CRL Charles River Laboratories International, Inc. Common Stock
$290.01
Price · Aug 19, 2026
Fundamentals as of Aug 5, 2026
52W Range
$144–$291
99% of range
Analyst Rating
BUY
22 analysts
Price Target
$281
P/E (TTM)
-99.7
ROE
-4.4%
Net Profit Margin
-3.6%
About Charles River Laboratories International, Inc. Common Stock Company overview from Wikipedia
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Read more
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M USD.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
CRL Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$290.00
Market Cap
$14.27B
P/E (TTM)
-99.7
EPS (TTM)
$-2.91
Revenue (TTM)
$4.02B
Div Yield
—
ROE
-4.4%
Debt/Equity
0.0
52W Range
$144 – $291
CRL Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
$4.02B
2016-12-31
→
2025-12-27
EPS
$-2.91
2016-12-31
→
2025-12-27
Free Cash Flow
$518M
2016-12-31
→
2025-12-27
Margins
-3.6%
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
CRL
Peer Median
P/E (TTM)
-99.7
39.9
P/S (TTM)
3.6
5.6
P/B
4.5
4.1
EV / EBITDA
32.8
—
Price / FCF
27.5
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
CRL
Peer Median
Operating Margin
0.63%
—
Net Profit Margin
-3.6%
11.7%
ROA
-2.0%
4.7%
ROE
-4.4%
8.5%
ROIC
1.1%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
CRL
Peer Median
Debt / Equity
0.0
15.3
Current Ratio
1.3
1.7
Quick Ratio
0.8
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
CRL
Peer Median
Revenue YoY
-0.85%
—
Revenue CAGR 3Y
0.33%
—
Revenue CAGR 5Y
6.6%
—
EPS YoY
-97.8%
—
Net Income YoY
-95.3%
—
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
CRL
Peer Median
CRL Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
22 analysts
- Strong Buy 5 22.7%
- Buy 10 45.5%
- Hold 7 31.8%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
14 analysts · 2026-08-14
Median
$300.00
Mean
$281.00
Now
$290.00
Low
$145.00
High
$318.00
Median target
$300.00
+3.4%
Mean target
$281.00
-3.1%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.21%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $3.02 | $2.76 | 0.26% |
| March 31, 2026 | $2.06 | $1.96 | 0.10% |
| Dec. 31, 2025 | $2.39 | $2.37 | 0.02% |
| Sept. 30, 2025 | $2.43 | $2.36 | 0.07% |
| June 30, 2025 | $3.12 | $2.52 | 0.60% |
| March 31, 2025 | $2.34 | $2.10 | 0.24% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | — |
| TECH | $7.97B | 111.8 | 5.2% | 6.0% | 3.7% | 64.8% |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | — |
| BIO | — | — | — | — | — | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 15
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
Balance Sheet 30
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
Cash Flow 18
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
Profitability 7
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
Liquidity & Solvency 5
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
Efficiency 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
Growth Rates 7
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
Valuation (TTM) 14
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
Income Statement 14
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | -99,475,000 | 49,213,000 | 49,149,000 | 50,677,000 | -103,002,000 | 51,394,000 | 51,551,000 | 51,437,000 | 28,000 | 51,283,000 | 51,097,000 | -101,521,000 | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | -100,031,000 | 49,426,000 | 49,316,000 | 50,853,000 | -103,643,000 | 51,583,000 | 51,846,000 | 51,842,000 | -42,000 | 51,607,000 | 51,428,000 | -102,590,000 | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
Balance Sheet 28
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
Cash Flow 16
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
Profitability 5
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
Liquidity & Solvency 4
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
Efficiency 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
Valuation (TTM) 13
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.04B | $4.02B | · | $4.03B | $4.05B | $4.03B | · | $4.07B | $4.12B | $4.13B | · | $4.11B | $3.91B | · | $3.77B | |
| Net Income TTM | $90M | $117M | · | $202M | $242M | $262M | · | $324M | $351M | $360M | · | $384M | $402M | · | $402M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | 117.9 | 67.4 | · | 37.2 | 32.4 | 31.9 | · | 32.7 | 31.2 | 39.3 | · | 26.2 | 25.8 | · | 23.9 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | · | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| P / FCF | · | -516.9 | · | · | · | 68.0 | · | · | · | 275.0 | · | · | · | · | · | |
| EV / EBITDA | 54.0 | 40.0 | · | 32.4 | 32.8 | 38.0 | · | 48.3 | 44.1 | 64.5 | · | 43.0 | · | · | 41.4 | |
| EV / FCF | · | -504.4 | · | · | · | 65.9 | · | · | · | 268.6 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.5 | 3.3 | · | 2.4 | · | · | 2.5 | |
| Earnings Yield | 0.85% | 1.5% | · | 2.7% | 3.1% | 3.1% | · | 3.1% | 3.2% | 2.5% | · | 3.8% | 3.9% | · | 4.2% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Operating Margin % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| Net Income | $-144M | $22M | $475M | $486M | $391M |
| Diluted EPS | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
Balance Sheet
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
Cash Flow
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 617 filers · $7.8B total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 82 (-8 vs prior Q) | 61 (-20 vs prior Q) | 180 (-11 vs prior Q) | 201 (+13 vs prior Q) | -972K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| FMR LLC | $737,350,307 | 3,251,247 | 9.42% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $714,227,026 | 3,149,288 | 9.12% | Shares |
| HARRIS ASSOCIATES L P | $508,269,048 | 2,241,144 | 6.49% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501,427,927 | 2,210,979 | 6.40% | Shares |
| STATE STREET CORP | $422,800,968 | 1,864,284 | 5.40% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $348,883,077 | 1,538,354 | 4.46% | Shares |
| CITADEL ADVISORS LLC | $270,696,771 | 1,193,601 | 3.46% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $259,130,041 | 1,144,937 | 3.31% | Shares |
| EARNEST PARTNERS LLC | $254,007,295 | 1,120,011 | 3.24% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $223,361,616 | 984,883 | 2.85% | Shares |
| AMERIPRISE FINANCIAL INC | $192,886,814 | 850,503 | 2.46% | Shares |
| NEUBERGER BERMAN GROUP LLC | $192,182,793 | 847,488 | 2.45% | Shares |
| Clearbridge Investments, LLC | $177,185,527 | 781,276 | 2.26% | Shares |
| COOKE & BIELER LP | $171,369,328 | 755,630 | 2.19% | Shares |
| VICTORY CAPITAL MANAGEMENT INC | $150,762,735 | 664,768 | 1.93% | Shares |
| MILLENNIUM MANAGEMENT LLC | $110,324,717 | 486,462 | 1.41% | Shares |
| BANK OF AMERICA CORP /DE/ | $104,921,899 | 462,639 | 1.34% | Shares |
| Gotham Asset Management, LLC | $98,233,181 | 433,146 | 1.25% | Shares |
| Amundi | $93,528,650 | 412,402 | 1.19% | Shares |
| NORGES BANK | $83,921,372 | 370,040 | 1.07% | Shares |
| MARSHALL WACE, LLP | $76,947,125 | 339,288 | 0.98% | Shares |
| Iron Triangle Partners LP | $75,748,141 | 379,728 | 0.97% | Shares |
| ALLIANCEBERNSTEIN L.P. | $64,615,913 | 374,585 | 0.83% | Shares |
| SNYDER CAPITAL MANAGEMENT L P | $63,899,443 | 281,756 | 0.82% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63,174,169 | 278,558 | 0.81% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $63,095,473 | 278,211 | 0.81% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $61,384,115 | 270,665 | 0.78% | Shares |
| PRIMECAP MANAGEMENT CO/CA/ | $60,523,448 | 266,870 | 0.77% | Shares |
| GOLDMAN SACHS GROUP INC | $57,319,812 | 252,744 | 0.73% | Shares |
| Meridiem Capital Partners LP | $56,012,367 | 246,979 | 0.72% | Shares |
| Alyeska Investment Group, L.P. | $53,295,650 | 235,000 | 0.68% | Shares |
| Quantinno Capital Management LP | $49,020,824 | 216,150 | 0.63% | Shares |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $48,415,129 | 213,480 | 0.62% | Shares |
| Boston Trust Walden Corp | $46,506,918 | 205,066 | 0.59% | Shares |
| Burgundy Asset Management Ltd. | $45,453,909 | 278,329 | 0.58% | Shares |
| SRS Investment Management, LLC | $42,496,817 | 187,384 | 0.54% | Shares |
| LOOMIS SAYLES & CO L P | $38,517,487 | 169,838 | 0.49% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $37,184,513 | 172,350 | 0.47% | Shares |
| PERCEPTIVE ADVISORS LLC | $31,750,600 | 140,000 | 0.41% | Shares |
| LAKEWOOD CAPITAL MANAGEMENT, LP | $30,389,860 | 134,000 | 0.39% | Shares |
| NEW YORK STATE COMMON RETIREMENT FUND | $29,879,583 | 131,750 | 0.38% | Shares |
| BlackRock, Inc. | $29,025,945 | 127,986 | 0.37% | Shares |
| PICTON MAHONEY ASSET MANAGEMENT | $26,340,305 | 116,144 | 0.34% | Shares |
| FIL Ltd | $25,184,576 | 111,048 | 0.32% | Shares |
| Candriam S.C.A. | $23,824,478 | 105,152 | 0.30% | Shares |
| Clark Capital Management Group, Inc. | $23,010,567 | 101,462 | 0.29% | Shares |
| Vanguard Global Advisers, LLC | $22,453,344 | 99,005 | 0.29% | Shares |
| Swiss National Bank | $22,452,210 | 99,000 | 0.29% | Shares |
| CONFLUENCE INVESTMENT MANAGEMENT LLC | $20,491,384 | 90,354 | 0.26% | Shares |
| ENVESTNET ASSET MANAGEMENT INC | $20,280,546 | 89,424 | 0.26% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19,730,730 | 87,000 | 0.25% | Call option |
| NOMURA HOLDINGS INC | $19,672,672 | 86,744 | 0.25% | Shares |
| RHUMBLINE ADVISERS | $19,484,825 | 85,916 | 0.25% | Shares |
| Ilex Capital Partners (UK) LLP | $18,413,760 | 81,193 | 0.24% | Shares |
| Aristotle Capital Boston, LLC | $18,273,438 | 80,574 | 0.23% | Shares |
| CITADEL ADVISORS LLC | $17,485,509 | 77,100 | 0.22% | Call option |
| NICHOLAS COMPANY, INC. | $16,305,067 | 71,895 | 0.21% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $15,172,024 | 66,899 | 0.19% | Shares |
| Mitsubishi UFJ Asset Management Co., Ltd. | $15,164,087 | 66,864 | 0.19% | Shares |
| Ranger Investment Management, L.P. | $15,009,416 | 66,182 | 0.19% | Shares |
| California Public Employees Retirement System | $14,670,818 | 64,689 | 0.19% | Shares |
| Assenagon Asset Management S.A. | $14,020,385 | 61,821 | 0.18% | Shares |
| ASSETMARK, INC | $13,939,194 | 61,463 | 0.18% | Shares |
| Rhenman & Partners Asset Management AB | $12,972,388 | 57,200 | 0.17% | Shares |
| RIVERBRIDGE PARTNERS LLC | $12,859,587 | 56,703 | 0.16% | Shares |
| TD Asset Management Inc | $12,854,230 | 56,679 | 0.16% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $12,836,314 | 56,600 | 0.16% | Put option |
| Laurus Investment Counsel Inc. | $12,365,663 | 71,685 | 0.16% | Shares |
| KING LUTHER CAPITAL MANAGEMENT CORP | $12,204,023 | 53,812 | 0.16% | Shares |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $11,552,133 | 50,938 | 0.15% | Shares |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $10,732,081 | 47,278 | 0.14% | Shares |
| RAYMOND JAMES FINANCIAL INC | $10,506,727 | 46,328 | 0.13% | Shares |
| VANGUARD ASSET MANAGEMENT, Ltd | $10,472,482 | 46,177 | 0.13% | Shares |
| KENNEDY CAPITAL MANAGEMENT LLC | $9,914,950 | 43,719 | 0.13% | Shares |
| BARCLAYS PLC | $9,909,816 | 43,696 | 0.13% | Shares |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $9,827,670 | 56,972 | 0.13% | Shares |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $9,382,529 | 41,371 | 0.12% | Shares |
| Park West Asset Management LLC | $9,343,748 | 41,200 | 0.12% | Shares |
| State of Tennessee, Department of Treasury | $8,457,000 | 37,290 | 0.11% | Shares |
| J.P. Marvel Investment Advisors, LLC | $8,456,092 | 37,286 | 0.11% | Shares |
| CASTLEARK MANAGEMENT LLC | $8,174,646 | 36,045 | 0.10% | Shares |
| JANE STREET GROUP, LLC | $7,869,613 | 34,700 | 0.10% | Call option |
| Pine Ridge Advisers LLC | $7,710,860 | 34,000 | 0.10% | Shares |
| PRUDENTIAL FINANCIAL INC | $7,346,635 | 32,394 | 0.09% | Shares |
| Capricorn Fund Managers Ltd | $7,092,630 | 31,274 | 0.09% | Shares |
| STATE OF WISCONSIN INVESTMENT BOARD | $7,000,554 | 30,868 | 0.09% | Shares |
| FIRST TRUST ADVISORS LP | $6,951,290 | 30,651 | 0.09% | Shares |
| Caption Management, LLC | $6,803,700 | 30,000 | 0.09% | Put option |
| Engineers Gate Manager LP | $6,637,463 | 29,267 | 0.08% | Shares |
| LAWSON KROEKER INVESTMENT MANAGEMENT INC/NE | $6,351,027 | 28,004 | 0.08% | Shares |
| Midwest Trust Co | $6,091,126 | 26,858 | 0.08% | Shares |
| VAN ECK ASSOCIATES CORP | $5,942,578 | 26,203 | 0.08% | Shares |
| SEI INVESTMENTS CO | $5,929,630 | 26,150 | 0.08% | Shares |
| Sendero Wealth Management, LLC | $5,909,468 | 26,057 | 0.08% | Shares |
| 13D Management LLC | $5,851,182 | 25,800 | 0.07% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $5,500,853 | 31,889 | 0.07% | Shares |
| D. E. Shaw & Co., Inc. | $5,462,691 | 24,087 | 0.07% | Shares |
| INVESTMENT HOUSE LLC | $5,447,042 | 24,018 | 0.07% | Shares |
| LPL Financial LLC | $5,409,169 | 23,851 | 0.07% | Shares |
| LRT Capital Management, LLC | $5,348,842 | 23,585 | 0.07% | Shares |
Company insiders 57 insiders · 21 officers · 27 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Glenn Coleman | EVP & Chief Financial Officer | May 29, 2026 A | 27,752 | 0 | 0 | $0 |
| Flavia Pease | Corporate Executive VP & CFO | May 31, 2025 F | 17,297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | March 3, 2022 M | 25,819 | 0 | 0 | $0 |
| Davide Molho | President & COO | July 24, 2018 M | 17,155 | 0 | 0 | $0 |
| Mark Mintz | EVP, Chief Information Officer | May 31, 2026 F | 9,546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | Nov. 7, 2024 G | 23,337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | June 1, 2020 A | 3,171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | May 29, 2020 A | 224,478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | Oct. 1, 2016 F | 5,599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | March 2, 2016 S | 11,034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | Feb. 25, 2015 M | 14,094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | Aug. 11, 2010 F | 74,390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | Feb. 26, 2010 A | 31,897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | Aug. 11, 2007 F | 37,109 | 0 | 0 | $0 |
| David J Elliott | Officer | June 29, 2007 M | 11,750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | May 1, 2007 A | 6,262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | April 2, 2007 A | 11,500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | April 2, 2007 F | 12,713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | Feb. 23, 2007 A | 12,710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | Feb. 27, 2006 S | 16,134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | Dec. 23, 2004 M | 8,000 | 0 | 0 | $0 |
| Steven Barg | Director | June 2, 2026 A | 3,287 | 0 | 0 | $0 |
| Nancy C Andrews | Director | May 12, 2026 G | 3,964 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | Director | May 8, 2026 A | 4,563 | 0 | 0 | $0 |
| George Llado | Director | May 8, 2026 A | 6,702 | 0 | 0 | $0 |
| Abraham Ceesay | Director | May 8, 2026 A | 2,384 | 0 | 0 | $0 |
| Mark J Enyedy | Director | May 8, 2026 A | 2,384 | 0 | 0 | $0 |
| Paul W Graves | Director | May 8, 2026 A | 2,384 | 0 | 0 | $0 |
| Craig B. Thompson | Director | May 8, 2026 A | 3,851 | 0 | 0 | $0 |
| Martin Mackay | Director | May 8, 2026 A | 17,137 | 0 | 0 | $0 |
| Virginia M Wilson | Director | May 8, 2026 A | 6,349 | 0 | 0 | $0 |
| George Massaro | Director | May 15, 2025 S | 5,575 | 0 | 0 | $0 |
| Richard F Wallman | Director | Nov. 7, 2024 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | Director | May 13, 2024 A | 7,894 | 0 | 0 | $0 |
| Robert J Bertolini | Director | May 13, 2024 A | 32,802 | 0 | 0 | $0 |
| Richard C Reese | Director | May 15, 2023 A | 65,541 | 0 | 0 | $0 |
| George M Milne JR | Director | May 7, 2021 A | 29,079 | 0 | 0 | $0 |
| Stephen D Chubb | Director | Feb. 23, 2021 M | 40,529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | Director | May 22, 2019 A | 3,886 | 0 | 0 | $0 |
| William Waltrip | Director | Dec. 5, 2012 S | 21,830 | 0 | 0 | $0 |
| Samuel O Thier MD | Director | May 9, 2012 A | 18,230 | 0 | 0 | $0 |
| Douglas E Rogers | Director | May 7, 2010 A | 12,859 | 0 | 0 | $0 |
| Nancy T Chang | Director | May 7, 2010 A | 31,010 | 0 | 0 | $0 |
| Linda Mcgoldrick | Director | Feb. 13, 2006 A | — | 0 | 0 | $0 |
| Walter S Nimmo | Director | Feb. 25, 2005 S | 149,447 | 0 | 0 | $0 |
| John Urquhart | Director | Feb. 17, 2005 A | 11,738 | 0 | 0 | $0 |
| Louise S Mccrary | Director | Feb. 17, 2005 A | — | 0 | 0 | $0 |
| Robert Cawthorn | Director | June 2, 2004 G | 278,600 | 0 | 0 | $0 |
| Shannon M Parisotto | — | Aug. 11, 2026 M | 4,807 | 0 | 2 | $-2,365,755 |
| Birgit Girshick | — | Aug. 11, 2026 M | 36,013 | 0 | 1 | $-1,819,350 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 6 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 filings | Aug. 4, 2011 | — | Initial filing | — | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 filings | Feb. 9, 2011 | — | Initial filing | — | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 filings | Dec. 7, 2010 | — | Initial filing | — | SEC |
| Undisclosed reporting person | June 16, 2010 | — | Initial filing | — | SEC |
| Undisclosed reporting person | June 7, 2010 | — | Initial filing | Passive investment | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | May 5, 2010 | — | Initial filing | Board campaign | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 134 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.49% | 4,749 NS | April 30, 2026 | N-PORT |
| EPSB · Harbor ETF Trust | 1.33% | 370 NS | April 30, 2026 | N-PORT |
| EPMV · Harbor ETF Trust | 1.09% | 291 NS | April 30, 2026 | N-PORT |
| EPSV · Harbor ETF Trust | 0.90% | 270 NS | April 30, 2026 | N-PORT |
| TAX · EA Series Trust | 0.80% | 1,131 NS | May 29, 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.66% | 612 NS | April 30, 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0.50% | 2,356 NS | April 30, 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.38% | 11,925 NS | April 30, 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.33% | 6,161 NS | April 30, 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0.29% | 22,440 NS | April 30, 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0.26% | 212,321 NS | April 30, 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.22% | 8,115 NS | April 30, 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0.17% | 24,528 NS | April 30, 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0.17% | 133,341 NS | May 31, 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.16% | 138,243 NS | April 30, 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.15% | 18,369 NS | April 30, 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.15% | 6,079 NS | May 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.13% | 22,674 NS | April 30, 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0.13% | 59,338 NS | April 30, 2026 | N-PORT |
| RXL · ProShares Trust | 0.13% | 513 NS | May 31, 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0.12% | 2,082 NS | April 30, 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.12% | 982 NS | April 30, 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.11% | 3,280 NS | April 30, 2026 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 0.11% | 1,032 NS | April 30, 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0.09% | 1,986 NS | May 31, 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.07% | 5,261 NS | April 30, 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0.06% | 20,810 NS | April 30, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.06% | 1,328 NS | April 30, 2026 | N-PORT |
| SPXD · DBX ETF Trust | 0.05% | 19 NS | May 31, 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.05% | 41,210 NS | April 30, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.04% | 105,382 NS | April 30, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.03% | 5,627 NS | April 30, 2026 | N-PORT |
| SCHV · SCHWAB STRATEGIC TRUST | 0.03% | 24,676 NS | May 31, 2026 | N-PORT |
| GVUS · Goldman Sachs ETF Trust | 0.03% | 591 NS | May 31, 2026 | N-PORT |
| SNPE · DBX ETF Trust | 0.02% | 3,759 NS | May 29, 2026 | N-PORT |
| EGLE · Global X Funds | 0.02% | 3 NS | April 30, 2026 | N-PORT |
| CHRI · Global X Funds | 0.02% | 7 NS | April 30, 2026 | N-PORT |
| DEUS · DBX ETF Trust | 0.02% | 337 NS | May 29, 2026 | N-PORT |
| SPXT · ProShares Trust | 0.02% | 328 NS | May 31, 2026 | N-PORT |
| FNDX · SCHWAB STRATEGIC TRUST | 0.02% | 30,460 NS | May 31, 2026 | N-PORT |
| QRFT · Exchange Listed Funds Trust | 0.02% | 19 NS | April 30, 2026 | N-PORT |
| FNDB · SCHWAB STRATEGIC TRUST | 0.02% | 1,472 NS | May 31, 2026 | N-PORT |
| SPUS · Tidal Trust I | 0.02% | 3,014 NS | May 31, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.02% | 2,431 NS | April 30, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.02% | 10,974 NS | April 30, 2026 | N-PORT |
| SPXN · ProShares Trust | 0.02% | 69 NS | May 31, 2026 | N-PORT |
| JUST · Goldman Sachs ETF Trust | 0.01% | 455 NS | May 31, 2026 | N-PORT |
| SPXE · ProShares Trust | 0.01% | 67 NS | May 31, 2026 | N-PORT |
| DSPY · Tema ETF Trust | 0.01% | 697 NS | May 31, 2026 | N-PORT |
| XRMI · Global X Funds | 0.01% | 41 NS | April 30, 2026 | N-PORT |